HSP90AA1 and neoplasm: In addition, it shows anti-tumour activity without detectable ocular toxicities in rats unlike other HSP90 inhibitors.37 These data suggest that TAS-116 has potential for clinical use; however, the mechanism underlying TAS-116 activity is still unclear.